Home     Useful Links     Promotion Activities     Contact          ?????

Organisation active in
ICT, Electronic, Telecomm135 
Ind. Technology, Material176 
Energy162 
Security & Environment225 
Transport & Aeronautics57 
Food & Agriculture206 
Biotech & Medicine265 
Technical sciences87 
None technical209 

 Organisation Profiles
 Serbia449 
 Montenegro43 
 Bosnia-Herzegovina179 
 FYR of Macedonia242 
 Croatia70 
 Albania35 
 Other24 
 Total1042 

 Profiles accessed
 Today321  
 Last week5052  
 Last month20620  
 Last year193901  

Prepare for printing     
Institute of Radiotherapy and Oncology
Medical Faculty
Oncology

 Contact data
StreetVodnjanska 17 
ZIP, City, State 1000 - Skopje (FYR of Macedonia) 
Phone+389 2 3147874 
Fax+389 2 3111430 
Emailsmicko@mt.net.mk 
Webwww.oncology.org.mk 
 Contact person

Professor Dr. PhD Snezana Smickoska (Chief of the Departement)
 Activities in Research and Development

 RTD sectors:
» Medicine and Health     

 Area of expertise (keywords)
» Oncology
» radiotherapy
» breast cancer
» lung cancer
 RTD Experiences

 Description of RTD activities
List of publication published in international journals:


1. Smickoska S, Jovanovski D. CONCURRENT RADIOTHERAPY AND CHEMOTHERAPY SCHEDULE IN SMALL CELL LUNG CANCER, LIMITED DISEASE Annals of oncology 5 (Suppl. 8), 1994, 167.

2. Smickoska S, Jovanovski D, Nikolic S. THE SERUM LEVEL OF TUMOR MARKERS (CEA, TPA, NSA, CA 19-9 ) IN SMALL-CELL LUNG CANCER PATIENTS. The European Journal of Cancer, vol 29A, Suppl. 6, 158, 1993.

3. Smickoska S, Jovanovski D, ALTERNATING VERSUS CONCURRENT RADIOTHERAPY AND CHEMOTHERAPY SCHEDULE IN SMALL CELL LUNG CANCER LIMITED DISEASE The European Respiratory Journal, Vol 8, Suppl. 19, 1995, 20s.

4. Smickoska S, Jovanovski D. CHEMOTHERAPY VERSUS CONCURRENT RADIO-CHEMOTHERAPY SCHEDULE IN SMALL CELL LUNG CANCER LIMITED DISEASE. The European Journal of Cancer, Vol 31A, Suppl.5, S22, 1995.

5. Smickoska S, Jovanovski D. RADIOTHERAPY IN MACEDONIA Int J of Radiation Oncology Biol Phys, Vol 35, No 5,1073-1074, 1996

6. Smickoska S, Jovanovski D. POLICY OF TREATMENT OF SMALL-CELL LUNG CANCER, LIMITED DISEASE. CONCURRENT RADIOTHERAPY CHEMOTHERAPY SCHEDULE Balcan Congress of Oncology, Athens, p.921-926, Copyright by Monduzzi Editore S. P. A. Bologna, Italy, July 3-7, 1996.

7. Smickoska S, Jovanovski D. ROLE OF HIGH DOSE RADIOTHERAPY IN THE MANEGEMENT OF SUPERIOR SULCUS NON-SMALL CELL LUNG CANCER, The European Journal of Cancer, Vol 9, Suppl.307s, 1996.

8. Smickoska S, Jovanovski D. RADIOTHERAPY IN MANAGEMENT OF PARAPARESIS CAUSED BY THALASSEMIA MAJOR (CASE REPORT) Radiotherapy and Oncology, Vol. 43 (Suppl. 2), S97, 1997.

9. Smickoska S, Jovanovski D, Mickovska V. CONCURRENT RADIOTHERAPY AND CHEMOTHERAPY SCHEDULE IN MALIGNANT MESOTHELIOMA 17th International Cancer Congress, Rio de Janeiro, p.689-693, Copyright by Monduzzi Editore S. P. A. Bologna, Italy, August 24-28, 1998

10. Nikolova L, Dimitrovska A, Smickoska S, Mickovska V, Trajkova S. HORMONAL, RADIATION, AND CHEMOTHERAPY IN THE TREATMENT OF PROSTATE CANCER 17th International Cancer Congress, Rio de Janeiro, August 24-28, Abstract book, p.265, 1998

11. Jovanovski D, Smickoska S, Crvenova S. RESPONSE OF SUPERIOR VENA CAVA SYNDROME DUE TO NON-SMALL CELL-LUNG CANCER TO RADIATION THERAPY 17th International Cancer Congress, Rio de Janeiro, p.6?-?, Copyright by Monduzzi Editore S. P. A. Bologna, Italy, August 24-28, 1998

12. Jovanovski D. Smickoska S. Crvenova S. THE INFLUENCE OD SEX, AGE AND HISTOLOGY ON TREATMENT RESULTS OD RADICALLY TREATED PATIENTS WITH LOCALLY ADVANCED, NON-SMALL CELL LUNG CANCER. The European Journal of Cancer, Vol 31A, Suppl. 5, S229, 1995.

13. Jovanovski D, Smickoska S. ALTERNATING RADIOTHERAPY AND HEMOTHERAPY SCHEDULE IN SMALL CELL LUNG CANCER, LIMITED DISEASE Annals of oncology 5 (Suppl. 8), 1994, 167.

14. Petrusevska G, Ilievska B, Banev S, Smickoska S, Spirovski Z. IMMUNOHISTOCHEMICAL EXPRESSION OF HER-2/neu IN PATIENTS WITH LUNG CARCINOMA AND ITS PROGNOSTIC SIGNIFICANCE. Radiol Oncol 38(2): 131-5, 2004

15. The International Adjuvant Lung Cancer Trial Collaborative Group. CISPLATIN-BASED ADJUVANT CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED NON-SMALL-CELL LUNG CANCER. The New England Journal of Medicine, Vol.350, No.4, 351-360, 2004

16. Jasar G, Basevska N, Kraleva S, Vasev N, Smickoska S, Zografski G. ASSOTIATION BETWEEN HER2/neu EXPRESSION AND HORMONE RECEPTOR STATUS IN BREST CANCER PATIENTS. Acta clin Croat, Vol. 41, No.2, 161, 2002

17. Jasar G, Basevska N, Kraleva S, Vasev N, Smickoska S, Zografski G. HER2/neu EXPRESSION IN CORELLATION WITH p53 AND Ki-67 IMMUNOREACTIVITY AND CLINICOPATOLOGICAL PARAMETERS IN BREST CANCER PATIENTS. Archive of Oncology Vol 10, Suppl 1:32, 2002

18. Vasev N, Maneva L, Smickoska S, Arsovski O, Stojkovski I. CAPECITABINE SECOND-LINE MONOTHERAPY FOR METASTATIC BREAST CANCER. EJC, Vol 3, No 2, 133, 2005

19. Ugrinska A, Kraleva S, Petrova D, Smickoska S, Vaskova O. TUMOR MARKERS AND BONE SCAN IN BREAST CANCER PATIENTS. World Journal of Nuclear Medicine Vol 3, Suppl 1:222, 2004.

20. Krstevska V, Smickoska S, Crvenkova S. ALTERD FRACTIONATION REGIMENS IN PRIMARY RADIOTHERAPY FOR SQAMOUS CELL CARCINOMA OF LARYNX, OROPHARYNX AND HYPOPHARYNX-AN ANALYSIS OF PROGNOSTIC FACTORS FOR LOCOREGIONAL CONTROL AND SURVIVAL. Libri oncol, Vol. 32 (2004), No 1-3, 1-6.

21. Stojkovski I, Smickoska S, Kraleva S, Arsovski O, Krstevska V, Vasev N. CAPECITABINE MONOTHERAPY AS SECOND LINE CHEMOTHERAPY IN PATIENTS WITH LIVER METASTASIS FROM BREAST CANCER. 6th Congress Balacan Union of Oncolgy, Sep. 2006, Proceedings, PP48, p.47.

22. Aceva L, Smickoska S, Nikolova L, Pesevska M, Milanovska L. CONCURRENT RADIOCHEMOTHERAPY FOR TRANSITIONAL CELL BLADER CANCER 6th Congress Balacan Union of Oncolgy, Sep. 2006, Proceedings, OP144, p.74.

 Experiences in international Programmes
1. Phase II study evaluating efficacy and safety of doxorubicin plus Taxol (paclitaxel) combination as first line treatment for patients with metastatic breast cancer
(prospective, phase II single center study-2000)
2. The International Adjuvant Lung Cancer Trial Collaborative Group. CISPLATIN-BASED ADJUVANT CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED NON-SMALL-CELL LUNG CANCER. The New England Journal of Medicine, Vol.350, No.4, 351-360, 2004
(a large scale trial evaluating adjuvant chemotherapy after curative resection of non-small cell lung cancer-june 1995)
3. A Phase III study of DPPE (Tesmilifene) combine with Epirubicin and Cyclophosphamide versus Epirubicin and Cyclophosphamide alone as first line Treatment in Metastatic/Recurrent Breast Cancer Pharm-Olam YMB 1002 - 02 Study (2005)
4. An expanded program of TarcevaTM (erlotinib, OSI-774) in treatment of patients with advanced stage IIIB/IV non-small-cell lung cancer
(an open-label, non-randomized, multicentre expanded access clinical trial of Tarceva as single agent, 2005)
IAEA projects
1. RER/6/008 BUILDING CAPACITY IN MEDICAL PHYSICS: FELLOWSHIP PROGRAMME
2. RER/6/009 MODERNIZATION AND IMPROVEMENT OF RADIOTHERAPY
3. RER/6/012 QUALITY ASSURANCE/QUALITY CONTROL IN RADIATION ONCOLOGY
4. МАК/6/007 ESTABLISHING HIGH DOSE RATE BRACHYTHERAPY

 Inserted / Updated
2007-09-03 / 2007-09-03